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Indocyanine green-mediated photothrombosis for
choroidal neovascularization in angioid streaks
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Purpose: To investigate the effect of indocyanine green-mediated photo-
thrombosis on choroidal neovascularization secondary to angioid streaks.
Methods: Six eyes of 5 patients with an average age of 70 years were
diagnosed to have subfoveal choroidal neovascularization secondary to
angioid streaks. Therapy was indicated if choroidal neovascularization
was considered to be active, according to evidence of fluorescein leakage
on angiograms, as well as presence of intra- or subretinal fluid on optical
coherence tomography. Patients received photothrombosis at baseline
with retreatment as necessary at 3, 6 and 9 months follow-up. Fluorescein
leakage was assessed at 3, 6 and 9 months, along with foveal thickness
measured by optical coherence tomography. Indocyanine green angio-
graphy was performed initially and whenever retreatment was considered.
Retreatment was performed whenever there was evidence of increased
leakage on fluorescein angiograms at follow-up visits. Results: The mean
follow-up was 13.3 months. All eyes had at least 12 months follow-up. Two
eyes underwent retreatment. Three eyes had visual acuity improvement
and three eyes had stabilization. All patients showed less fluorescein
leakage on final angiograms and reduced foveal thickness upon optical
coherence tomography measurement. Conclusion: Photothrombosis is a
feasible procedure for choroidal neovascularization secondary to angioid
streaks. Lesion analysis showed anatomical improvement in most cases in




The most serious ocular complication of angioid streaks is the occurrence
of choroidal neovascularization (CNV) in 72% to 86% of patients. CNV
becomes bilateral in approximately half of the cases within 18 months(1-2). The
natural prognosis of CNV associated with angioid streaks is not favorable, as
it usually involves scarring of the macula, resulting in loss of central vision
and formation of large scotomata(3). In these patients, macular damage leads
to half of the patients becoming legally blind by the age of 50(1).
Some studies demonstrated that laser photocoagulation of extrafoveal
or juxtafoveal, well-demarcated CNV may ultimately result in less severe
loss of vision compared with allowing a scar to form naturally(4-6). However,
management of lesions that extend under the fovea remains problematic.
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Poor preliminary results were obtained with most treatments
reported to date, including surgical approaches(7-8), transpu-
pillary thermotherapy (TTT)(9) and photodynamic therapy(10-15).
There are recent reports on the effect of angiogenesis inhibi-
tors in patients with CNV secondary to angioid streaks(16-17),
but they lack long-term results.
Indocyanine green-mediated photothrombosis (IMP) has
been used to treat CNV(18-21). It consists of selective thrombo-
sis of the choroidal neovascular membrane by laser delivery
after intravenous injection of indocyanine green (ICG). In the
present study, we investigated the efficacy of IMP for the
treatment of CNV in a group of patients with angioid streaks.
METHODS
This study was approved by the Ethics Committee of the
São Paulo Federal University, Brazil. It was a prospective,
non-comparative interventional case series. Written informed
consent was obtained from all patients. Six eyes of five pa-
tients, three male and two female, were treated. Their age
ranged between 43 and 76 years, with a mean of 70.
Patients with active subfoveal CNV associated with an-
gioid streak findings were included. Therapy was indicated if
CNV was considered to be active, according to evidence of
fluorescein leakage on angiograms, as well as presence of
intra- or subretinal fluid on optical coherence tomography
(OCT). Angioid streaks were defined as reddish or brownish
subretinal streaks radiating from the optic disc and possibly
associated with other abnormalities of the fundus, such as
orange-skin appearance or reticular retinal pigment epithelium
dystrophy at the posterior pole(1). Patients with signs of age-
related macular degeneration, such as confluent drusen, were
excluded. Other exclusion criteria included patients with
myopic fundus, intraocular inflammation and recent intraocu-
lar surgery (less than 3 months). Patients underwent complete
ocular examination including medical history, bestcorrected
visual acuity (BCVA), slit-lamp examination, tonometry, dila-
ted fundus photographs, fluorescein and ICG angiograms and
optical coherence tomography with Stratus OCT. ICG angio-
graphy was used to determine the lesion’s greatest linear
dimension (GLD) and ICG uptake at late phases (Figure 1).Vi-
sual acuity was measured in LogMAR units using ETDRS
charts. Pretreatment examinations, considered as baseline for
those included in the study, were completed within 7 days
before treatment. All patients were referred to the Dermato-
logy Department for systemic investigation and testing for
pseudoxanthoma elasticum.
The laser delivery was performed with VISULAS 810s (Carl
Zeiss Meditec AG, Jena, Germany), which consisted of a mo-
dified diode laser generating a wavelength of about 810 nm
(near infrared), near the maximum absorption peak of ICG,
coupled with a slit-lamp delivery system VISULINK TTT/U
and a slit-lamp biomicroscope (SL 120, Carl Zeiss Meditec AG,
Jena, Germany). Before any light application, a fundus contact
lens of 1.56 magnification (Mainster widefield, Ocular Instru-
ments, Bellevue, USA) was placed on the cornea.
The treatment technique has been previously described(18).
Briefly, the patients underwent treatment with a total dose of
2 mg/kg of ICG solution (Ophthalmos, São Paulo, Brazil). For
the procedure, a loading dose of a highly concentrated ICG
solution (25 mg/ml; approximately 1 mg/kg body weight) was
administered as an intravenous bolus, followed immediately
by a 5.0-ml saline flush. At 30 minutes after the loading dose, a
second intravenous injection of an identical solution was
administered, followed by a 5.0-ml saline flush. Two minutes
after the second flush infusion, a diode laser at 810 nm was
used at an intensity of 3.0 W/cm2 over 100 seconds to deliver
light to the fundus. Spot size was set with a 500-micron margin
on each side over GLD. At 20 minutes after the conclusion of
the first laser application, a light dose with the same parame-
ters was applied a second time to the exactly same position.
Patients were asked to return in one week for OCT evalua-
tion and then at 3-month intervals until completion of a 12-
month follow-up period for visual acuity, complete ophthal-
mological examination, fluorescein angiography and OCT.
The criteria for re-treatment were based on the presence of
leakage from CNV by fluorescein angiography or the presence
of intraretinal or subretinal fluid by OCT at each follow-up
visit. OCT was analyzed qualitatively and quantitatively,
using the “retinal map” foveal thickness algorithm.
Outcome evaluations were functional (BCVA) and anatomical
(clinical examination, fluorescein and ICG angiography patterns,
as well as foveal thickness measured by OCT). Criteria for BCVA
improvement or decrease were a difference of two or more ETDRS
lines; change in BCVA of one line was considered stabilization.
Treatment was considered successful if BCVA improve-
ment or stabilization was achieved within one-year follow-up.
Figure 1 - Indocyanine green late frame angiogram showing ICG uptake
by choroidal neovascular membrane. ICG angiograms were used to
 determine lesion size before treatment.
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RESULTS
Six eyes of five patients were treated. All neovascular mem-
branes were subfoveal.
Follow-up ranged from 52 to 80 weeks, with a mean of 56.6
weeks. A minimum of 12 months follow-up was obtained for all
eyes. Tables 1 and 2 summarize baseline characteristics as well
as changes in visual acuity and retinal thickness at each visit.
Dermatological results for pseudoxanthoma elasticum we-
re negative in all patients.
The pretreatment best corrected visual acuity scores ran-
ged from 20/80 to 20/800. Initial GLD ranged 2.47 to 6.75 mm,
with an average of 4.95 mm.
Three eyes showed stabilization of visual acuity, while the
other three eyes showed improvement of visual acuity, with
post-treatment visual acuity ranging from 20/50 to 20/800.
Among these three eyes, two eyes experienced three-line, and
one eye, two-line improvement.
At the last follow-up visit, fluorescein leakage was decrea-
sed in all six eyes. Three eyes presented with a fibrous scar
and three eyes progressed to some chorioretinal atrophy.
Among these eyes with chorioretinal atrophy, two of them
had a pigment alteration corresponding to the laser spot.
OCT analysis at the last follow-up visit showed decreased
foveal thickness in all eyes (range 194-385 µ), in comparison to
pretreatment thickness (range 220-504 µ). Two out of six trea-
ted eyes required two treatment sessions during the study
period, while the other four required only one session. Re-
treatment was performed at 3 months in one eye and at 9
months in others. No adverse events were observed during
ICG administration.
DISCUSSION
This study revealed that IMP for CNV secondary to angioid
streaks attained a successful outcome, since 3 out of 6 eyes had
BCVA improvement and 3 had stabilization. All eyes had
diminished fluorescein leakage and retinal thickness at the last
visit. IMP was shown to carry a favorable safety profile, since
no eyes showed any decrease in visual acuity, and no patients
experienced severe adverse effects. Nevertheless, many eyes
had a poor visual acuity at the last visit. Poor prognosis in
subfoveal neovascular membranes in angioid streaks may be
attributed to collagen changes seen in these patients, as well as
compromised adhesion of the retinal pigment epithelium (RPE)
basal membrane to the inner portion of Bruch’s membrane.
Hence, choroidal neovascularization has little resistance to late-
ral growth under the RPE, resulting in large membranes(22).
IMP using small volume infusions of a highly concentra-
ted ICG solution and low irradiance with a large-spot 810 nm
diode laser delivered by slit lamp has been shown to reduce
vision loss in CNV(18-21). To the best of our knowledge, there is
no study in the literature reporting the results of IMP for CNV
secondary to angioid streaks. Our study differs from a pre-
viously reported series(23) in that the previous study used in-
growth site ICG-mediated photothrombosis (ISIMP), which is
a different technique, and a different laser unit (Trimode-L;
OPTO, São Carlos, Brazil)(24).
The mechanisms of action of IMP are not completely known.
It is hypothesized(18) that a mixed type I (heat generation) and
type II (singlet oxygen formation) photooxidation effect may
explain the therapeutic effects of IMP, which is selective for
neovascularization.
Table 1. Demographic and clinical data of patients with CNV due to angioid streaks
ID Age Gender Time of complaint Status of other eye Type of CNV Greatest linear dimension at baseline (mm)
1 43 M 1 month Disciform Classic 3.58
2 74 F 6 months CNV OD occult 6.72
OS occult 6.75
3 62 M 2 months Normal Occult 4.40
4 76 M 6 months Disciform Occult 5.81
5 65 F 8 months Polypoidal Minimally classic 2.47
CNV= choroidal neovascularization
Table 2. BCVA, foveal thickness and time of follow-up of patients with CNV due to angioid streaks
ID Eye Initial Final Initial foveal Final foveal Follow-up Re-treat Lesion analysis
BCVA BCVA  thickness  thickness (months)
1 OS 20/800 20/200 504 315 12 No Fibrous scar
2 OD 20/400 20/200 411 251 20 Yes (9 m) Fibrous scar
2 OS 20/100 20/50 304 227 12 No Fibrous scar
3 OD 20/800 20/800 493 194 12 No Chorioretinal atrophy†
4 OD 20/80 20/63 220 219 12 Yes (3 m) Chorioretinal atrophy
5 OD 20/200 20/320 255 181 12 No Chorioretinal atrophy†
†
= atrophy corresponding to the laser spot; BCVA= bestcorrected visual acuity
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Currently, other treatment modalities for subfoveal CNV
secondary to angioid streaks have failed to show good re-
sults(3-9). Photodynamic therapy with verteporfin has been per-
formed recently for this disease, although without strong evi-
dence of efficacy(10-15). In the latter studies, most of the eyes
showed severe loss of vision after one year follow-up, where
either a large disciform scar or progression of exudative disea-
se was observed in these eyes. Results reported after intravi-
treal injection of bevacizumab are promising(16-17), but long-
term studies are needed.
Most patients included in this study had a poor visual
acuity at baseline. Initial VA was equal to or worse than 20/200
in 4 out of 6 eyes. These eyes had large lesions with an average
GLD of 4.95 mm. Patients had visual complaints for long pe-
riods before treatment (range 1-8 months, average 3.8 mon-
ths). All these facts may account for some poor visual acuity
prognosis. Nevertheless, final BCVA was better than at the
initial visit in three out of six eyes. Considering the poor
prognosis associated with choroidal neovascularization se-
condary to angioid streaks, with most patients becoming le-
gally blind by age 50(1), these results must be highlighted.
The decreased retinal thickness and diminished fluores-
cein leakage that we found in all eyes of our study may also be
interpreted as a natural history of the disease rather than the
treatment effect. These results cannot be used as an evidence
to demonstrate a positive effect of IMP on the arrest of disea-
se progression because there was no control group in which
we could see the natural history. Nevertheless, natural history
is usually not associated with vision improvement such as
that observed in this series.
On the other hand, two eyes developed some chorioretinal
atrophy (Figure 2) corresponding to the laser spot, which can
be considered photothermal injury(25) and hence an adverse
event. One of these eyes had a lower BCVA at the final visit,
while the other showed stabilization. Thermal laser injuries are
produced by high laser irradiances in brief exposures ranging
from microseconds to several seconds. We analyzed retros-
pectively this adverse event and found no relation to any of
the following pretreatment features that might have been res-
ponsible for this injury, such as patient age, time of complaint,
the size of lesion, presence of subretinal blood, fluid, fibrosis,
RPE and skin hyperpigmentation. It is accepted that, for some
laser treatments such as TTT, laser irradiance varies signifi-
cantly over the observed range of axial length(26). Therefore, it
is likely that in some hyperopic eyes with a short axial length
the laser irradiance during TTT using an indirect condensing
laser lens will be significantly higher than when using the
same spot and the same laser power in an emmetropic eye.
However, patients enrolled in this present study did not show
significant differences in their axial lengths. For that reason,
we could not attribute this adverse effect to a short axial length
as may be the case with TTT(26). Since all eyes underwent
treatment using the same laser parameters, with variation concer-
ning only spot size according to GLD, the answer to the question
why some eyes underwent such atrophy remains obscure.
CONCLUSION
IMP is not yet an approved treatment, since it lacks multi-
center randomized studies proving its efficacy. However, it
has been proved to be a low-risk, well-tolerated treatment for
CNV secondary to many diseases with a potential in achieving
visual acuity stabilization and limiting central vision loss in
different diseases complicated by CNV. This series comprised
a small number of patients, which limits our conclusions. A
multicenter IMP trial is currently underway, and it may help to
establish the role of this treatment in the CNV scenario. If our
preliminary data should be confirmed by the multicenter trial,
IMP may turn out to be a good option for CNV treatment, with
an excellent cost-effectiveness.
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RESUMO
Objetivo: Investigar os efeitos da fototrombose mediada por
indocianina verde sobre a neovascularização de coróide se-
cundária a estrias angióides. Métodos: Seis olhos de 5 pacien-
tes com média de 70 anos de idade tinham o diagnóstico de
neovascularização de coróide secundária a estrias angióides.
O tratamento foi indicado para neovascularização de coróide
ativa, avaliada pelo vazamento na angiofluoresceinografia e
pela presença de fluido intra ou sub-retiniano pela tomografia
de coerência óptica. Os pacientes receberam tratamento inicial
com indocianina verde, e a seguir foram re-tratados conforme
necessário com 3, 6 e 9 meses. Nessas ocasiões avaliava-se o
vazamento e a espessura foveal. A angiografia com indocia-
nina verde foi realizada inicialmente e sempre que o re-trata-
mento era considerado, nos casos em que havia aumento de
vazamento pela angiofluoresceinografia nas visitas de segui-
mento. Resultados: O tempo médio de seguimento foi de 13,3
meses. Todos os olhos atingiram um seguimento de pelo me-
nos 12 meses. Dois olhos foram submetidos a re-tratamento.
Três olhos apresentaram melhora e três olhos apresentaram
estabilização da acuidade visual. Todos os pacientes apresen-
taram diminuição final do vazamento e da espessura foveal.
Conclusão: Indocianina verde é procedimento factível para o
tratamento de neovascularização de coróide secundária a es-
trias angióides. A análise das lesões mostrou melhora
anatômica na maioria dos casos desta série. Mais estudos são
necessários para avaliar os resultados a longo prazo deste
tratamento.
Descritores: Estrias angióides; Neovascularização coroidal/
quimioterapia; Verde de indocianina; Fotoquimioterapia;
Agentes fotossensibilizantes/uso terapêutico; Lasers; Tomo-
grafia de coerência óptica
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